10-Q quarterly report · filed Nov 3, 2026

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 10-Q Quarterly Report

Short answer

Tarsus Pharmaceuticals, Inc. (TARS) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $195M (up 63.9% year over year) with net income of −$668M.

Q3 2026 key financials · XBRL

Revenue
$195M
+63.9% YoY · +11.9% QoQ
Net income
−$668M
−5210.6% YoY · −3502.7% QoQ
Operating margin
-340.3%
EPS (diluted)
−$15.08
−5100.0% YoY · −3407.0% QoQ

Source: XBRL data from the Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 10-Q on SEC EDGAR. USD.

Tarsus Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $194.6M vs $118.7M, up 64% YoY, entirely from XDEMVY product sales
  • Gross margin 93% vs 93% YoY; net loss $668.3M vs $12.6M
  • XDEMVY best performer: $194.6M sales, up 64% YoY; refills 20% of prescriptions
  • Cash, equivalents and marketable securities $309.6M; nine-month operating cash flow $30.6M vs $(31.8)M
  • Outlook: Kore and Calliope topline results expected first half 2027; vendor expenses expected to increase during remainder of 2026

Risk Factors

  • Newly added acquisition risk: July 6 and September 4, 2026 acquisitions of iRenix and Alkeus created integration and contingent payment exposure
  • Most materially updated trade risk: 2026 tariffs could reach 100%, reduced to 20% under a Commerce agreement subject to onshoring compliance
  • Regulatory compliance risk: Medicaid, 340B, Medicare, VA and DoD pricing errors could trigger rebates, penalties, False Claims Act liability, or program exclusion
  • Near-term operational risk: TP-04 and TP-05 require costly clinical development, with TP-05 Phase 3 needing thousands of patients
  • Financial risk: Alkeus carries a potential $250.0 million regulatory milestone payment, payable in cash or common stock

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Tarsus Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.